Otonomy, Inc. (OTIC)

Market Cap	6.75M
Revenue (ttm)	n/a
Net Income (ttm)	-52.26M
Shares Out	57.15M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,077,162
Open	0.112
Previous Close	0.109
Day's Range	0.108 - 0.123
52-Week Range	0.060 - 2.590
Beta	1.46
Analysts	Buy
Price Target	9.18 (+7,673.07%)
Earnings Date	Feb 27, 2023

About OTIC

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the pr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 13, 2014
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: OTIC

Financial Performance

In 2021, Otonomy's revenue was $125,000, a decrease of -54.21% compared to the previous year's $273,000. Losses were -$51.18 million, 14.4% more than in 2020.

Analyst Forecast

According to 7 analysts, the average rating for OTIC stock is "Buy." The 12-month stock price forecast is $9.18, which is an increase of 7,673.07% from the latest price.

Price Target

$9.18

(7,673.07% upside)

Analyst Consensus: Buy